- Home
- CLB vs TLRY Comparison
CLB vs TLRY Comparison
Compare CLB & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLB | TLRY |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | Canada |
| Employees | 3300 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.2M | 688.9M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CLB | TLRY |
|---|---|---|
| Price | $14.25 | $5.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $12.50 | ★ $72.33 |
| AVG Volume (30 Days) | 498.7K | ★ 5.7M |
| Earning Date | 04-29-2026 | 04-01-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $526,520,000.00 | N/A |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | $4.75 | $19.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.51 | N/A |
| 52 Week Low | $9.72 | $0.36 |
| 52 Week High | $20.36 | $15.70 |
Technical Indicators
Market Signals| Indicator | CLB | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 36.07 |
| Support Level | $13.72 | $1.12 |
| Resistance Level | $17.05 | $7.01 |
| Average True Range (ATR) | 0.61 | 0.21 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 78.90 | 23.88 |
Price Performance
Historical ComparisonAbout CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.